Citation Impact
Citing Papers
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
1999
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer Statistics, 2021
2021 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
2000 Standout
A view on drug resistance in cancer
2019 StandoutNature
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia
2003 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
P‐glycoprotein (PGP), lung resistance‐related protein (LRP) and multidrug resistance‐associated protein (MRP) expression in acute promyelocytic leukaemia
2000
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study
1990 StandoutNobel
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Triggering and modulation of apoptosis by oxidative stress
2000 Standout
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non‐small‐cell lung cancer
1996
Cancer Statistics, 2006
2006 Standout
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
2002
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma
2008 Standout
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
1993
Targeting multidrug resistance in cancer
2006 Standout
Molecular targets in the National Cancer Institute drug screen
1995
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
1997
Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia
2001
Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study
1999
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
2001
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
1989 StandoutNobel
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
1996 Standout
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
2009
Acute Myeloid Leukemia
1999
Cancer as an evolutionary and ecological process
2006 Standout
Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer
2009 Standout
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells
1999
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia
2011
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
2005
Wound repair and regeneration: Mechanisms, signaling, and translation
2014 Standout
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.
1997
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.
1987
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
2001 Standout
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
1981 StandoutNobel
Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia
1999
Acute Myeloid Leukemia
2015 Standout
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
2015
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Prognostic effect of weight loss prior tochemotherapy in cancer patients
1980 Standout
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered
1999
Cooperative sequestration of m-AMSA in L1210 cells
1982 StandoutNobel
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
2006
High‐dose cytosine arabinoside in the treatment of acute myeloid leukemia
2006
Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide
1987 Standout
The importance of dose intensity in chemotherapy of metastatic breast cancer.
1984 Standout
Factors related to length of complete remission in adult acute leukemia
1980
Toward the potential cure of leukemias in the next decade
2018
Paullones, a Series of Cyclin-Dependent Kinase Inhibitors: Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity
1999 Standout
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
1987 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia
2017
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
2001 Standout
High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults
1981
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
4′-(9-Acridinylamino) Methanesulfon-m-Anisidide (AMSA): A New Drug Effective in the Treatment of Adult Acute Leukemia
1980
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia
2014
Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non-lymphocytic leukemia in adults
1980
A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).
1995 StandoutNobel
Cancer treatment and survivorship statistics, 2019
2019 Standout
Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy
1997
New agents in non-small cell lung cancer
1984
Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials
2005
High-dose cytosine arabinoside therapy for refractory leukemia
1983
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
1998 Standout
WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).
2005
Metabolism of oxazaphosphorines
1988
Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C.
1987
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin
1978
Formation and resealing of intercalator-induced DNA strand breaks in permeabilized L1210 cells without the stimulated synthesis of poly(ADP-ribose).
1982 StandoutNobel
Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
1984
Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia
1980
Ifosfamide in refractory male germ cell tumors.
1986
Immunomodulatory treatment in patients with rheumatic diseases: Mechanisms of action
1987
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
2014
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
2013
Chemotherapy in Advanced Breast Carcinoma Comparison Between Doxorubicin-Cyclophosphamide and Cyclophosphamide-Methotrex-Ate-5-Fluorouracil-Vincristine-Prednisone
1985
Works of J. Bickers being referenced
Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma.
1981
A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study.
1995
Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response
1974
The Effect of Prolonged Plasmapheresis on Immunoglobulins, other Serum Proteins, Delayed Hypersensitivity and Phytohemagglutinin-Induced Lymphocyte Transformation
1971
Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.
1981
Adriamycin combinations in advanced breast cancer:A southwest oncology group study
1982
Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia
1995
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
1996